3 ms·
I invested in a clinical trials company many years ago (operating an investigative site), and I'm curious what kind of traction you've gotten from the big pharm
by dsl 13y ago
I invested in a clinical trials company many years ago (operating an investigative site), and I'm curious what kind of traction you've gotten from the big pharmaceutical companies?
I totally get how it is a compelling story for investors, but I have serious doubts about adoption and use.
It was my experience that data and sound record keeping was a secondary to approvals. Many times paperwork was "corrected" and patients were excluded because of serious adverse events. Unless your model is to help identify exclusionary criteria retroactively?
- rmorrison 13y agoThe industry has been drastically changing over the past decade. 15 years ago, all data collection was paper based. Then came Electronic Data Collection systems. Now, there are cloud systems likes Medidata Rave and Veeva which are doing exceptionally well. This change has created tremendous opportunity for new startups. This is happening across all enterprise verticals, and this is why there is such an opportunity for enterprise startups. As Warren Hogarth says in the original article "There’s about a trillion dollars of enterprise software", much of which will "transition to [specialized] enterprise software... and create multi-billion dollar companies".